Monotherapy with valproate in primary generalized epilepsies.

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Primary generalized epilepsies present significant treatment challenges.
• Many patients require effective monotherapy for seizure control.
• Prior drug therapies may be limited by efficacy or adverse effects.

Purpose of the Study:

• To evaluate the efficacy and tolerability of sodium valproate enteric-coated tablets as monotherapy for primary generalized epilepsies.
• To assess the impact of sodium valproate on seizure frequency and electroencephalogram (EEG) paroxysmal activity.
• To determine the optimal duration for trialing sodium valproate before considering alternative treatments.

Main Methods:

• A cohort of 118 patients with primary generalized epilepsies received sodium valproate monotherapy.
• Patients were followed for a median of 17 months, with dosage adjusted to <20 mg/kg/day.
• Seizure control, EEG findings, and adverse events were systematically recorded.

Main Results:

• 83% of patients achieved seizure freedom at a mean daily dosage below 20 mg/kg.
• High efficacy was observed for tonic-clonic seizures (85%), absences (82%), and myoclonic seizures (82%).
• EEG paroxysmal activity decreased from 88% to 32.4%, and side effects were mild and transient in 16% of patients initially, decreasing to 2%.

Conclusions:

• Sodium valproate monotherapy is a highly effective treatment for primary generalized epilepsies.
• The drug demonstrates broad-spectrum efficacy against major seizure types and improves EEG findings.
• Adequate trial periods are crucial for maximizing the benefits of sodium valproate before switching medications.